Quick answers
- What is Humulin R U-500 KwikPen?
- Humulin R U-500 KwikPen is a brand name of Insulin human, a prescription medicine. The FDA NDC Directory lists 1 Humulin R U-500 KwikPen product in 1 strength and form.
- Who makes Humulin R U-500 KwikPen?
- Lilly holds the FDA application for Humulin R U-500 KwikPen (BLA018780, approved October 28, 1982).
- Is there a generic or store brand of Humulin R U-500 KwikPen?
- Other products of Insulin human are listed with the FDA, but none in exactly the same strength and form as a Humulin R U-500 KwikPen product.
- What do pharmacies pay for Humulin R U-500 KwikPen?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 1 Humulin R U-500 KwikPen strength and form (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Humulin R U-500 KwikPen been recalled?
- No recall linked to Humulin R U-500 KwikPen products (by their NDC code or label) appears in the FDA enforcement reports we use.
What Humulin R U-500 KwikPen is
Each Humulin R U-500 KwikPen product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Insulin human · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| insulin human 500 units/mL injection, solution (subcutaneous) | Humulin R U-500 KwikPen | None listed | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Insulin human →
FDA approval
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| BLA018780 | Lilly | October 28, 1982 | 1 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| insulin human 500 units/mL injection, solution | Brand: Humulin R U-500 KwikPen | $91.60 per mL |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Humulin R U-500 KwikPen
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Humulin R U-500 KwikPen products.
- Eli Lilly and Company1 product
Recalls
No recall linked to Humulin R U-500 KwikPen products (by their NDC code or label) appears in the FDA enforcement reports.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.